AI주식인사이트AI Stock Insight
C

선바이오

067370KOSDAQ의약품 제조업

44.0 / 100

Reference Date: 2026-07-24

Financial Score14.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Slightly down 2.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

SunBio focuses on developing and selling PEG-filgrastim (a neutropenia treatment), MucoPEG (a xerostomia treatment), and artificial blood SBX, along with producing and selling PEG derivatives. PEG-filgrastim is under U.S. approval proceedings, while MucoPEG faces delays in U.S. market entry due to patent issues. The company is also advancing research on solid electrolytes for lithium-ion batteries and aims to enhance competitiveness through a new factory in Incheon.

Number of Employees

29people

Average Salary

51.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
26.24Industry Average 11.230.0Point

2.3x industry avg (risky)

PBR
2.54Industry Average 0.810.0Point

3.1x industry avg (risky)

ROE
9.99Industry Average 4.017.0Point

2.5x industry avg (excellent)

Debt Ratio
35.91Industry Average 12.430.0Point

2.9x industry avg (risky)

Trend 2023~20257.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.1% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲467.1% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 9.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (31%)

Current 6,010Won52-week high 8,29052-week low 4,945
1-month return2.0Point

1m -2.28% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral기업설명회(IR)개최2026-07-07